Hancock Whitney Corp Reduces Position in Edwards Lifesciences Co. (NYSE:EW)

Hancock Whitney Corp trimmed its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 33.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 20,379 shares of the medical research company's stock after selling 10,362 shares during the period. Hancock Whitney Corp's holdings in Edwards Lifesciences were worth $1,509,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Harbor Capital Advisors Inc. raised its holdings in Edwards Lifesciences by 2.5% in the fourth quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company's stock worth $824,000 after buying an additional 273 shares during the last quarter. Nordea Investment Management AB raised its holdings in Edwards Lifesciences by 34.6% in the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company's stock worth $301,355,000 after buying an additional 1,043,484 shares during the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST raised its holdings in Edwards Lifesciences by 6.7% in the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company's stock worth $355,344,000 after buying an additional 300,000 shares during the last quarter. Sivik Global Healthcare LLC purchased a new position in Edwards Lifesciences in the fourth quarter worth about $3,702,000. Finally, Avanza Fonder AB purchased a new position in Edwards Lifesciences in the fourth quarter worth about $4,845,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

EW has been the subject of several recent analyst reports. Canaccord Genuity Group lifted their target price on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a report on Friday, April 25th. Truist Financial reduced their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research note on Friday, April 11th. Piper Sandler upgraded shares of Edwards Lifesciences from a "neutral" rating to an "overweight" rating and lifted their price target for the stock from $73.00 to $80.00 in a research note on Thursday, April 24th. Morgan Stanley lifted their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Wednesday, February 12th. Finally, Robert W. Baird lifted their price target on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research note on Thursday, April 24th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, Edwards Lifesciences has an average rating of "Hold" and a consensus price target of $79.45.

Insider Transactions at Edwards Lifesciences

In related news, CEO Bernard J. Zovighian sold 6,164 shares of Edwards Lifesciences stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $69.51, for a total value of $428,459.64. Following the completion of the transaction, the chief executive officer now owns 59,083 shares in the company, valued at approximately $4,106,859.33. This trade represents a 9.45 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the transaction, the chief financial officer now owns 30,561 shares of the company's stock, valued at approximately $2,315,301.36. This represents a 26.91 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 71,853 shares of company stock valued at $5,163,062. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Price Performance

Shares of EW traded down $0.21 during mid-day trading on Thursday, reaching $75.28. The stock had a trading volume of 1,019,462 shares, compared to its average volume of 4,985,847. The firm has a market cap of $44.25 billion, a price-to-earnings ratio of 10.79, a PEG ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.25. The business has a fifty day moving average of $71.03 and a 200 day moving average of $71.23. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The company had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same period in the previous year, the firm posted $0.66 EPS. Edwards Lifesciences's revenue for the quarter was up 6.2% compared to the same quarter last year. Equities analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.